Brown R W, Allred C D, Clark G M, Osborne C K, Hilsenbeck S G
Department of Pathology, The Methodist Hospital, Houston, Texas 77030, USA.
Clin Cancer Res. 1996 Mar;2(3):585-92.
The primary purpose of this study was to evaluate the prognostic significance of Ki-67, a cell proliferation-associated antigen, in a large group (n = 674) of axillary node-negative breast cancer cases with long-term follow-up and to correlate Ki-67 antigen expression with S-phase fraction. Ki-67 immunostaining was assessed both semiquantitatively and quantitatively. The statistical analysis focused on agreement between methods of Ki-67 quantification, agreement between Ki-67 and S-phase fraction, associations between Ki-67 and other clinical variables, and prognostic value of Ki-67. There was excellent agreement between the two methods of Ki-67 assessment (Spearman rank correlation, rsp = 0.91; P = 0.0001; n = 674) but only weak correlation between either semiquantitative or quantitative Ki-67 and S-phase fraction (rsp = 0.12 and rsp = 0.15, respectively). Ki-67 (overall median, 2%) was independent of tumor size and modestly related to other measures of tumor aggressiveness. Using a cutpoint of 5% (percentage of tumor cells), cases with high Ki-67 exhibited a significantly shorter disease-free survival (Padj = 0.004). In multivariate analysis, high Ki-67 was associated with a 1.8-fold increased risk of recurrence (P = 0.001). In the subgroup with S-phase data, the adjusted relative risk (hazard ratio, 1.9; P = 0.02) was unchanged by inclusion of S phase in the model. This suggests that Ki-67 provides significant independent prognostic information in addition to that contained in tumor size and S-phase fraction.
本研究的主要目的是评估细胞增殖相关抗原Ki-67在一大组(n = 674)腋窝淋巴结阴性乳腺癌病例中的预后意义,这些病例均有长期随访,并将Ki-67抗原表达与S期细胞分数相关联。对Ki-67免疫染色进行了半定量和定量评估。统计分析聚焦于Ki-67定量方法之间的一致性、Ki-67与S期细胞分数之间的一致性、Ki-67与其他临床变量之间的关联以及Ki-67的预后价值。Ki-67评估的两种方法之间具有极佳的一致性(Spearman等级相关性,rsp = 0.91;P = 0.0001;n = 674),但半定量或定量的Ki-67与S期细胞分数之间仅存在弱相关性(分别为rsp = 0.12和rsp = 0.15)。Ki-67(总体中位数为2%)与肿瘤大小无关,与其他肿瘤侵袭性指标呈适度相关。以5%(肿瘤细胞百分比)为切点,Ki-67高表达的病例无病生存期显著缩短(Padj = 0.004)。在多变量分析中,Ki-67高表达与复发风险增加1.8倍相关(P = 0.001)。在有S期数据的亚组中,模型纳入S期后,调整后的相对风险(风险比,1.9;P = 0.02)未改变。这表明Ki-67除了提供肿瘤大小和S期细胞分数所包含的信息外,还提供了显著的独立预后信息。